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Background: The incidence of malignancies in kidney transplant recipients is increasing. Breast cancer is a
common malignancy after kidney transplantation and can be more aggressive in kidney transplant recipients than
in the general population. In this study, we evaluated the incidence and prognosis of breast cancer in kidney
transplant recipients.
Findings: Between 1993 and 2013, 750 kidney transplant patients were followed-up at our center. Since 1999,
annual physical examination, mammography, and breast ultrasonography have been performed for such patients.
Diagnostic studies, including core needle or mammotome biopsy, were performed for suspected malignancies.
Patients with malignant neoplasm were administered the appropriate treatment and followed-up to assess tumor
response and symptoms.
Nine patients were diagnosed with breast cancer during the follow-up period. The mean age at the initial detection of
the breast cancer was 47.7 ± 8.4 years. The mean interval from transplantation to diagnosis was 148.7 ± 37.1 months.
Of the 9 patients, 8 were detected through the screening test; 7 were treated with breast conservative surgery and 1
was treated with modified radical mastectomy. The cancer stages were 0 (n = 2), I (n = 6), and II (n = 1). The incidence
of breast cancer tended to be unchanged with time between transplantation and diagnosis, inconsistent with the
increase in the duration of immunosuppression.
Conclusion: Annual screening tests are crucial in the early diagnosis of breast cancer. Early treatment of breast cancer
can result in an excellent prognosis in kidney transplant recipients.
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Advances in the development of immunosuppressive
agents have significantly reduced the acute rejection rate
and markedly improved graft survival in kidney trans-
plantation (Meier-Kriesche et al. 2004). Despite these en-
couraging trends, the long-term patient survival rate
after kidney transplantation has remained unchanged
(Webster et al. 2008; Campistol 2009). The high mortal-
ity among kidney transplant recipients (KTRs) is attrib-
uted mainly to cardiovascular disease and malignancy* Correspondence: kakuta@uro.med.osaka-u.ac.jp
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in any medium, provided the original work is p(Campistol 2009). Over the next decade, the mortality
rate from malignancy among transplant recipients will
exceed that from cardiovascular disease (Buell et al.
2005). In Europe and North America, the chronic use of
immunosuppressants is associated with an increasing
rate of malignancy after kidney transplantation (Grulich
et al. 2007; Engels et al. 2011; Van Leeuwen et al. 2010).
Although the greatest relative increase was observed in
the risks of non-melanoma skin cancers and cancers as-
sociated with viral infection, the risk of more common
solid organ cancers also significantly increased among
patients with a relative risk compared with the general
population (Webster et al. 2008; Kasiske et al. 2004;
Vajdic et al. 2006).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ger at diagnosis and have poorer outcomes than the gen-
eral population (Buell et al. 2002). BC is the most
common cancer and the leading cause of cancer-related
death worldwide. Major risk factors include age, family
history, and long-term hormonal replacement therapy,
which have been strongly linked to cancer stage at diag-
nosis (Ferlay et al. 2010). In Japanese women between
the ages of 40 and 59 years, BC is the leading cause of
death, which is considered a growing social problem
(Matsuda et al. 2013). However, relatively few studies
have addressed the occurrence of BC in KTRs. It re-
mains controversial whether screening tests can reduce
BC development after kidney transplantation. In this
study, although the number of cases was limited, we
aimed to evaluate the efficacy of conducting screening
tests for BC in KTRs.
Patients and methods
Subjects
Between 1993 and 2013, 750 kidney transplant patients
underwent routine follow-up with or without screening
at our kidney transplant center. All the clinical data of
the KTRs were obtained from our department database.
Among the patients, 77 developed de novo malignancy
(6 with double cancers) and 9 were diagnosed with BC.
Patient characteristics are shown in Table 1. All the pa-
tients were closely monitored by performing screening
tests. In particular, all the female patients were followed-
up annually from 1999 through physical examination,
mammography (MMG), and breast ultrasonography
(USG). Diagnostic evaluations, including a core needle
or mammotome biopsy, were performed for suspected
malignancies. Patients with a malignant neoplasm were
administered the appropriate treatment and followed-up
to assess tumor response and symptoms. All the BC pa-
tients were women who underwent surgery between
1998 and 2013.
The study protocol was approved by the Institutional
Review Board of Osaka University Hospital (approval no.
14150).Table 1 Baseline characteristics of kidney transplant
recipients
Total Recipients BC
Total number 750 9
Age at transplant 38.6 ± 13.3 47.7 ± 2.8
Gender (M/F) 454/296 0/9
Duration to diagnosis (months) 148.7 ± 37.1
Duration of dialysis (years) 3.7 ± 0.2 4.9 ± 0.9
Donor type (Living/Cadaveric) 557/193 7/2
Duration of follow-up (years) 8.8 ± 2.4 6.7 ± 4.9
BC: Breast cancer.Statistical analysis
Kaplan-Meier estimates were used to calculate patient
and graft survival rates. The primary end-point was
death (overall survival [OS]). OS was defined as the time
from diagnosis of BC to death. Statistical significance
was determined using the chi-square test. Differences
were considered statistically significant at p < 0.05.
Results
Malignancy
The overall incidence of malignancy, including multiple
primary malignancy, during the follow-up period was
10.3% (77/750 patients). The mean recipient age was
43.6 ± 12.8 years, with 31.4% of the patients aged >50 years.
The mean interval from transplantation to diagnosis was
134.5 ± 11.3 months. Other characteristics of the patients
are described in Table 1.
Incidence of BC
BC was diagnosed in 9 female recipients (11.7% of all
malignancy cases) but in none of the male recipients.
The mean age at the initial detection of BC was 47.7 ±
8.4 years. The mean interval from the time of transplant-
ation to diagnosis was 148.7 ± 37.1 months.
The demographic characteristics of the KTRs with BC
are described in Table 2. In 8 of the 9 patients, BC was
detected using a screening test. The BC patients un-
derwent breast-conserving surgery (n = 7) or modified
radical mastectomy (n = 2). The cancer stages were 0
(n = 2), I (n = 6), and II (n = 1). Four patients received
adjuvant endocrine therapy depending on their hormone
receptor-positive status. None of the patients received
adjuvant chemotherapy. Seven patients received therapy
with mycophenolate mofetil and calcineurin inhibitors
(CNIs) immediately after kidney transplantation. Of the
9 patients, 2 were administered azathioprine as an anti-
metabolite. Since 2004, 3 patients have received induc-
tion therapy with anti-CD25 antibodies. None of the
patients experienced acute rejection episodes. Adjust-
ment of immunosuppressants was not required after BC
diagnosis.
Eight patients were asymptomatic at the time of BC
diagnosis, which was detected during the routine screen-
ing test. Before the screening system was introduced in
1999, 1 patient felt her own breast mass in 1998. The
cancer stages were 0 (n = 2), I (n = 5), and II (n = 1) in
the patients diagnosed through the screening test. The
patients diagnosed by using the screening test were
treated with breast-conservative surgeries (n = 7) or
modified radical mastectomy (n = 1).
The incidence of BC remained unchanged with time
between transplantation and diagnosis, which did not
coincide with the increase in the duration of immuno-
suppressant treatment (Figure 1). After transplantation,
Table 2 Characteristics of breast cancers in kidney transplant recipients
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MGM: Mammography, USG: Ultrasonography.
CS: Conservative surgery, MRM: Modified radical mastectomy.
ER: Estrogen receptor, PR: Progesteron receptor, HER2: Human EFGR related-2.
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(2.2%) between 5 and 9 years, and in 3 patients (0.8%) at
>9 years. The 5-year survival rate was 100% for stage 0,
97.7% for stage I, and 100% for stage II, with no tumor re-
currence. After a median follow-up period of 56 months,
1 patient with double cancer died of uterine cancer.
Discussion
The incidence of cancer after kidney transplantation has
increased in recent years due to the increase in patient sur-
vival (Meier-Kriesche et al. 2004; Webster et al. 2008;Figure 1 Cumulative incidence rate of breast cancer (BC) after kidney transCampistol 2009; Grulich et al. 2007). Cancers in KTRs usu-
ally have a more aggressive feature, with rapid progression.
The most common cancers in KTRs were non-melanoma
skin cancer, urological cancer, and lymphoproliferative
disease (Meier-Kriesche et al. 2004; Webster et al. 2008;
Campistol 2009; Grulich et al. 2007; Vajdic et al. 2006).
Only few studies have evaluated the incidence of BC
post-renal transplantation, although several other cancers
have been known to occur more frequently after trans-
plantation (Kasiske et al. 2004; Birkeland et al. 2000;
Pedotti et al. 2003; Kauffman et al. 2006). KTRs seemed toplantation.
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(Agraharkar et al. 2004; Stewart et al. 1995). This could be
attributed to the intensive medical screening performed
before transplantation, resulting in the exclusion of high-
risk patients. Meanwhile, KTRs had undergone long-term
dialysis therapy before kidney transplantation. Therefore,
given that KTRs require immunosuppressants throughout
life, it is necessary to consider the incidence of cancer in
dialysis patients as a control group. Vajvic et al. compared
the incidence of cancer in KTRs with that in dialysis pa-
tients on the waiting list for transplantation. According to
the study, kidney transplantation did not increase the
risk of other types of cancer including BC although the
risk of skin cancer, Kaposi’s sarcoma and malignant
lymphoma is increased more than twice in KTRs.
However, Buell et al. also reported that while immuno-
suppression may not increase the incidence of BC, it
might increase the biological aggressiveness of BC (Buell
et al. 2002). These reports suggest that early detection of
BC may be important for the diagnosis of the disease at
an early stage and for initiating the appropriate therapy.
In the present study, the incidence of BC among the
KTRs was found to be 1.2% at a mean of 148.7 months
after transplantation. This rate is higher than that previ-
ously reported owing to our strict screening system,
which permitted the earlier detection of BC in our study
than in previous studies (Buell et al. 2002; Kwak et al.
2013; Popov et al. 2007). It is particularly worth noting
that 8 of 9 BC were detected after the screening system
was initiated in 1999. Among 8 screening-detected pa-
tients, 7 were treated with conservative surgery. One pa-
tient who was monitored through screening tests for
8 years underwent bilateral modified radical mastec-
tomy. In this case, the histology was noninvasive ductal
carcinoma, which is difficult to detect during screening.
The incidence of BC was unchanged despite the time
that lapsed after transplantation in the present study,
which is consistent with the previous reports (Buell et al.
2002; Agraharkar et al. 2004; Kwak et al. 2013). This
finding suggests that KTRs should continue to undergo
long-term screening after transplantation to improve pa-
tient outcomes. Generally, the morbidity of BC in Japan
is reported to be 103.6 per 100000 which is the most
common number in female population and Japanese
breast cancer society recommends that women over
40 years should receive BC screening. In the guidelines
for the management of transplant recipients, the screen-
ing test for BC is recommended for KTRs aged between
50 and 70 years (Kasiske et al. 2000; EBPG Expert Group
on Renal Transplantation 2002). However, considering
that the mean age at initial detection of BC in our study
was 47.7 years, we recommend that patients aged be-
tween 40 and 50 years should also undergo the screening
test in the same manner as general population.The benefits of MMG in the detection of BC have long
been established (Humphrey et al. 2002). However,
MMG has a serious limitation in that its rate of false-
negative results can be as high as 35%, especially in
women with dense breast tissue (Majid et al. 2003).
Moreover, most Japanese women have dense or hetero-
geneously dense breast on MMG compared to Western
women (Takamoto et al. 2013). This can lead to the pos-
sibility of missing a cancer lesion. At our center, we also
conduct breast USG to compensate for the weakness of
MMG and increase the discovery rate of early BC. Inter-
estingly, in some patients, USG clearly showed an ir-
regular and heterogenous nodule though no dominant
mass was detected in MMG. In Japan, a large clinical
study of adjunct USG is ongoing to address the issue of
BC mortality rate reduction (Ishida et al. 2014).
Management of patients by using immunosuppressant
drugs after BC diagnosis is a matter of concern. The
therapeutic benefit of reducing the dose of immunosup-
pressant drugs in patients with solid organ tumors is
controversial (Self et al. 2006). In some studies, CNI use
was not a risk factor of any type of malignancy (Marcen
et al. 2003). Moreover, the overall amount of immuno-
suppressant may not lead to an increased incidence of
BC (Buell et al. 2002). These findings suggest that de-
creasing the dose or discontinuation of immunosuppres-
sants may be unnecessary for the KTRs with BC after
diagnosis. In our cases, the dose of immunosuppresants
remained unchanged after BC diagnosis.
Renal graft function should be considered before che-
motherapy, as some chemotherapeutic agents can affect
graft function. Paclitaxel might be an appropriate option
for patients with impaired graft function. Data regarding
hormonal therapy in these patients are limited.
Recent studies suggest that the use of mammalian tar-
gets of rapamycin inhibitors (e.g., sirolimus and everoli-
mus) may reduce the overall risk of solid organ tumors
after kidney transplantation (Alberu et al. 2011; Piselli
et al. 2013). Furthermore, recent clinical trials reported
positive effects of everolimus in improving progression-
free survival in women with BC (Baselga et al. 2012). In
our center, since 2010, patients with stable renal function
who are receiving CNI have been converted to everolimus.
The potential protective effect would result in a reduced
incidence of BC after kidney transplantation.
Some limitations should be considered when inter-
preting our results. First, despite our sample size, we
had a limited number of BC cases (n = 9) in the KTRs
population. Second, the median follow-up period for
the KTRs with BC was inadequate. Finally, this was a
retrospective study; therefore, we could not control for
all confounding variables. However, it is notable that
this is the first study to evaluate the incidence of BC in
Japanese KTRs.
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KTRs with BC can be successfully treated using a min-
imally invasive modality. Although our sample size was
small, our experience shows that the patient prognosis
in BC is excellent if treatment is administered during
the initial stages. We highly recommend BC screening
for KTRs to facilitate early detection of BC.
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